Fig. 1.
TDAG8 gene expression is reduced in patients with blood cancers in comparison to healthy donor’s immune cells or leukocyte-rich tissue. a The expression of TDAG8 is reduced 4.5-fold in CD34+ bone marrow and CD34+ peripheral blood cells isolated from patients with AML (N = 20) in comparison to CD34+ bone marrow and CD34+ peripheral blood cells isolated from healthy donors (N = 26). b The expression of TDAG8 is reduced 2.9-fold in CD19+/CD5+ peripheral blood mononuclear cells isolated from patients with CLL (N = 11) in comparison to CD19+/CD5+ peripheral blood mononuclear cells isolated from healthy donors (N = 39). c The expression of TDAG8 is reduced 3.6-fold CD3+ peripheral blood cells (N = 8) isolated from patients with TCPLL in comparison to CD3+ peripheral blood cells isolated from healthy donors (N = 6). d The expression of TDAG8 is reduced 2.7-fold in CD19+ peripheral blood lymphocytes isolated from patients with CBLL (N = 6) in comparison to CD19+ peripheral blood lymphocytes isolated from healthy donors (N = 11). e The expression of TDAG8 is reduced by 3.0-fold in DLBCL biopsy samples (N = 73) in comparison to B-lymphocytes isolated from healthy donors (N = 9). The expression of TDAG8 is also reduced by 2.8-fold in human FL biopsy samples (N = 38) in comparison to B-lymphocytes isolated from healthy donors (N = 9). AML acute myeloid leukemia, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, TCPLL T-cell prolymphocytic leukemia with inv(14)(q11q32), CBLL chronic B-cell lymphocytic leukemia. Y-axis is Log2 scale. ***P < 0.001